Clinical Trials
72 trialsNCT01220583 2026-05-27
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery
Radiation Therapy Oncology Group
Phase 2 Active not recruiting
NCT05392608 2026-05-22
SEQUEL-Breast
Borstkanker Onderzoek Groep
Phase 2 Active not recruiting
NCT02724579 2026-05-20
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
Children's Oncology Group
Phase 2 Active not recruiting
NCT03817398 2026-05-20
Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia
Children's Oncology Group
Phase 2 Active not recruiting
NCT03134118 2026-05-15
NIVOTHYM
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Active not recruiting
NCT04001829 2026-05-15
Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT07085728 2026-05-15
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT03609047 2026-05-12
Appalaches
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Active not recruiting
NCT05694936 2026-05-08
Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer
Australasian Gastro-Intestinal Trials Group
Phase 2 Active not recruiting
NCT04647916 2026-05-06
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
SWOG Cancer Research Network
Phase 2 Active not recruiting
NCT06094140 2026-05-06
NEO-IMPACT
Australasian Gastro-Intestinal Trials Group
Phase 2 Active not recruiting
NCT04115631 2026-05-05
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT04166318 2026-05-05
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT04233866 2026-05-05
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT04266249 2026-05-05
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT04316117 2026-05-05
Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT04597359 2026-05-05
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT05710328 2026-05-05
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT02595424 2026-05-01
Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT05673187 2026-04-27
ADEPPT
ETOP IBCSG Partners Foundation
Phase 2 Active not recruiting
NCT05761171 2026-04-21
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
Children's Oncology Group
Phase 2 Active not recruiting
NCT02436707 2026-04-20
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT04166565 2026-04-20
EMN19
European Myeloma Network B.V.
Phase 2 Active not recruiting
NCT00951535 2026-04-17
A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0 M0 Prostate Cancer. ICORG 08-17
Cancer Trials Ireland
Phase 2 Active not recruiting
NCT04195399 2026-04-15
A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
Children's Oncology Group
Phase 2 Active not recruiting
NCT01244789 2026-04-13
Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer
Danish Gynecological Cancer Group
Phase 2 Active not recruiting
NCT03516279 2026-04-03
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT01898494 2026-04-01
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT03419234 2026-04-01
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT01396408 2026-03-27
A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT04663997 2026-03-27
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT03410615 2026-03-24
Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT04268550 2026-03-23
Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)
SWOG Cancer Research Network
Phase 2 Active not recruiting
NCT04904588 2026-03-18
ACCESS
Center for International Blood and Marrow Transplant Research
Phase 2 Active not recruiting
NCT02905318 2026-03-09
Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT04393285 2026-03-09
Abemaciclib and Letrozole to Treat Endometrial Cancer
GOG Foundation
Phase 2 Active not recruiting
NCT03057106 2026-03-03
Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT05154487 2026-03-03
A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
GOG Foundation
Phase 2 Active not recruiting
NCT01824875 2026-02-25
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT03794349 2026-02-18
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
Children's Oncology Group
Phase 2 Active not recruiting
NCT04176848 2026-02-18
CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT03822897 2026-02-17
EVADER
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT05714891 2026-02-12
Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT03965468 2026-02-09
CHESS
ETOP IBCSG Partners Foundation
Phase 2 Active not recruiting
NCT04743661 2026-02-05
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
Pediatric Brain Tumor Consortium
Phase 2 Active not recruiting
NCT06001385 2026-02-05
OPTIMIZE
Center for International Blood and Marrow Transplant Research
Phase 2 Active not recruiting
NCT03768570 2026-02-02
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT03624543 2026-01-30
CFI-400945 in Patients With Advanced/Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT05601973 2026-01-21
AMAZE-lung
ETOP IBCSG Partners Foundation
Phase 2 Active not recruiting
NCT03480776 2026-01-14
ASA in Prevention of Ovarian Cancer (STICs and STONEs)
Canadian Cancer Trials Group
Phase 2 Active not recruiting